Page last updated: 2024-11-05

phenyramidol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phenyramidol is a centrally acting muscle relaxant that was initially developed in the 1960s. It is a derivative of mephenesin, another muscle relaxant. Phenyramidol's mechanism of action is not fully understood, but it is believed to act on the central nervous system to reduce muscle spasms. Research suggests that phenyramidol may have potential applications in treating conditions like spasticity and muscle pain. However, its use has been limited due to concerns about its safety and efficacy. Studies have investigated its potential benefits and risks, but further research is needed to fully understand its therapeutic potential and safety profile.'

phenyramidol: considered as a drug that possibly causes hepatotoxicity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9470
CHEMBL ID1697767
CHEBI ID134888
SCHEMBL ID21963
MeSH IDM0455681

Synonyms (90)

Synonym
NSC17777 ,
.alpha.-[(2-pyridylamino)methyl]benzyl alcohol
nsc-23634
fenyramidol
553-69-5
evaspirine
phenyramidol
in 511
bonapar
2-(.beta.-hydroxyphenethylamino)pyridine
evasprine
abbolexin
evasprin
benzyl alcohol, .alpha.-[(2-pyridylamino)methyl]-
.alpha.-(2-pyridylaminomethyl)benzyl alcohol
cabral
miodar
nsc23634
vilexin
mj 505
phenylramidol
wln: t6nj bm1yqr
elan
benzenemethanol, .alpha.-[(2-pyridinylamino)methyl]-
NCI60_001490
feniramidolo [dcit]
alpha-(2-pyridylaminomethyl)benzyl alcohol
fenyramidolum [inn-latin]
feniramidol [inn-spanish]
benzyl alcohol, alpha-((2-pyridylamino)methyl)-
nsc 23634
einecs 209-044-7
fenyramidol [inn:ban]
2-(beta-hydroxyphenethylamino)pyridine
benzenemethanol, alpha-((2-pyridinylamino)methyl)-
brn 0169969
(+-)-phenyramidol
fenyramidol (van) (*hydrochloride*)
{.alpha.-[(2-pyridylamino)methyl]benzyl} alcohol monohydrochloride
fenyramidol (*hydrochloride*)
1-phenyl-2-(2-pyridinylamino)ethanol
benzenemethanol, {.alpha.-[(2-pyridinylamino)methyl]-,} monohydrochloride
{.alpha.-[(2-pyridylamino)methyl]benzyl} alcohol hydrochloride
1-phenyl-2-(2-pyridylamino)ethanol
benzyl alcohol, .alpha.-(2-pyridyl-aminomethyl)-, hydrochloride
benzyl alcohol, {.alpha.-[(2-pyridylamino)methyl]-,} monohydrochloride
CHEBI:134888
1-phenyl-2-(pyridin-2-ylamino)ethanol
D07953
fenyramidol (inn)
mj-505
CHEMBL1697767
1-phenyl-2-(pyridin-2-ylamino)-ethanol
AKOS008926639
feniramidolo
feniramidol
unii-r3v02wl7o3
r3v02wl7o3 ,
5-22-08-00301 (beilstein handbook reference)
fenyramidolum
benzyl alcohol, .alpha.-((2-pyridylamino)methyl)-
benzenemethanol, .alpha.-((2-pyridinylamino)methyl)-
phenyramidol [mi]
fenyramidol [inn]
fenyramidol [who-dd]
(+/-)-phenyramidol
SCHEMBL21963
alpha-[(2-pyridylamino)methyl]benzylalcoholmonohydrochloride
miodar (salt/mix)
pyridine, 2-(.beta.-hydroxyphenethylamino)-
abbolexin (salt/mix)
ZEAJXCPGHPJVNP-UHFFFAOYSA-N
(.+/-.)-phenyramidol
analexin (salt/mix)
elan (salt/mix)
1-phenyl-2-(2-pyridinylamino)ethanol #
FT-0699783
sr-01000944835
SR-01000944835-1
Z31268347
phenyramidol-hcl
bdbm235694
cabrale
Q5443698
DB13414
2-(4-isopropylphenylthio)benzoicacid
DTXSID00862185
phenyramidol (hydrochloride)
methyl?4-methyl-3,4-dihydro-2h-benzo[b][1,4]oxazine-7-carboxylate
1-phenyl-2-[(pyridin-2-yl)amino]ethan-1-ol

Research Excerpts

Overview

Phenyramidol is a moderately potent and relatively nontoxic analgesic with concomitant muscle-relaxant activity.

ExcerptReferenceRelevance
"Phenyramidol is a moderately potent and relatively nontoxic analgesic with concomitant muscle-relaxant activity. "( Phenyramidol-associated liver toxicity.
Filik, L; Köklü, S; Köksal, AS; Sahin, B; Sasmaz, N, 2003
)
3.2
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aminopyridineCompounds containing a pyridine skeleton substituted by one or more amine groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutathione reductase, mitochondrialHomo sapiens (human)Ki434.00000.80003.45006.1000AID1803039
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
cellular oxidant detoxificationGlutathione reductase, mitochondrialHomo sapiens (human)
cellular response to oxidative stressGlutathione reductase, mitochondrialHomo sapiens (human)
glutathione metabolic processGlutathione reductase, mitochondrialHomo sapiens (human)
cell redox homeostasisGlutathione reductase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
electron transfer activityGlutathione reductase, mitochondrialHomo sapiens (human)
NADP bindingGlutathione reductase, mitochondrialHomo sapiens (human)
glutathione-disulfide reductase (NADPH) activityGlutathione reductase, mitochondrialHomo sapiens (human)
flavin adenine dinucleotide bindingGlutathione reductase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
mitochondrial matrixGlutathione reductase, mitochondrialHomo sapiens (human)
cytosolGlutathione reductase, mitochondrialHomo sapiens (human)
external side of plasma membraneGlutathione reductase, mitochondrialHomo sapiens (human)
extracellular exosomeGlutathione reductase, mitochondrialHomo sapiens (human)
cytosolGlutathione reductase, mitochondrialHomo sapiens (human)
mitochondrionGlutathione reductase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1803039Activity Assay from Article 10.3109/14756366.2011.572879: \\In vitro effects of some drugs on human erythrocyte glutathione reductase.\\2012Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 27, Issue:1
In vitro effects of some drugs on human erythrocyte glutathione reductase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (77.78)18.7374
1990's0 (0.00)18.2507
2000's1 (5.56)29.6817
2010's3 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.88 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index66.76 (26.88)
Search Engine Supply Index1.99 (0.95)

This Compound (45.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (5.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (95.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]